Announcements Trials
Browse Landscape

Status

Completed 11Unknown 3Recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 73Observational 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 2NSCLC 1

Interventions

Blood Specimen Collection 87Surveys and Questionnaires 86Surgical Procedures, Operative 45Drug Therapy 33Radiotherapy 28Biopsy 26Neoadjuvant Therapy 24Amplified Fragment Length Polymorphism Analysis 24Immunohistochemistry 22Gene Expression Profiling 21Bevacizumab 19Magnetic Resonance Spectroscopy 17Immunotherapy 17Data Collection 17Ultrasonography 16Positron Emission Tomography Computed Tomography 16Liquid Biopsy 16pembrolizumab 15Observation 15Nivolumab 15Watchful Waiting 14Radiosurgery 14Microarray Analysis 14Magnetic Resonance Imaging 14Interviews as Topic 14Immune Checkpoint Inhibitors 14Colonoscopy 13Capecitabine 13Polymerase Chain Reaction 12Paclitaxel 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Observational × Erlotinib Hydrochloride × Clear all
NCT03647592 2023-12-27

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Hunan Province Tumor Hospital

Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04575415 2020-10-20

BELLA

Guangdong Association of Clinical Trials

Unknown
272 enrolled
Thoracic

NSCLC

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Sungkyunkwan University

Unknown
4,724 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡